CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer
Clinical trial NCT07383285 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07383285
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-01
- Primary completion
- 2029-12-31
- Enrollment
- 106
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.